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Background/Aims: Adalimumab is effective for both remis-
sion induction and the maintenance of Crohn’s disease (CD) 
in Western countries. We evaluated the efficacy of adalim-
umab in the conventional step-up treatment approach for CD 
in Korea. Methods: We retrospectively reviewed 62 patients 
with CD who were treated with adalimumab. Their Crohn’s 
disease activity index (CDAI) was measured at weeks 4, 
8, and 52. Clinical remission was defined as a CDAI score 
<150. Induction and maintenance outcomes were analyzed. 
Results: Forty-one patients (66.1%) achieved a reduction of 
70 CDAI points at week 8. Among them, 28 (45.2%) achieved 
clinical remission at week 8, 20 (32.3%) maintained remis-
sion at week 52. The absence of prior anti-tumor necrosis 
factor (TNF) therapy and Montreal classification L1 at base-
line predicted clinical remission at week 8 in the multivariate 
logistic regression analysis. In the Cox proportional hazards 
model, the hazard ratio for the secondary loss of response 
during maintenance therapy after clinical remission induction 
was significantly higher in patients who showed initial mild 
CDAI severity or Montreal classification A3. Conclusions: In 
our study, anti-TNF therapy-naive and Montreal classification 
L1 were associated with adalimumab efficacy as induction 
therapy in CD. Further studies are warranted to determine 
the prognostic factors for the long-term response after adali-
mumab therapy. (Gut Liver 2016;10:255-261)
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INTRODUCTION
Crohn’s disease (CD) is a chronic idiopathic inflammatory 
bowel disorder and its disease course fluctuates between clini-
cal remission and relapse. A considerable number of patients 
eventually require bowel resection and postoperative recurrence 
is very common.1 The conventional approach for induction and 
maintenance treatment for CD has changed since new biologic 
agents have been introduced. Monoclonal anti-tumor necrosis 
factor (TNF) antibodies have become a mainstay for CD treat-
ment during the last few decades.
In Asia, anti-TNF agents are used less frequently than they 
are in Western countries because of their limited, strict indica-
tions under insurance coverage rules and the social economic 
burden.2 Of the anti-TNF agents, infliximab and adalimumab 
were approved in Korea in 2003 and 2010, respectively. Inf-
liximab, a chimeric monoclonal immunoglobulin G1 antibody 
against TNF-α, was the first biologic agent approved for the 
treatment of CD in Korea. However, 10% to 30% of patients are 
primary nonresponders to infliximab, and its annual drop-out 
rate has been reported to be 20% to 40% because of the loss 
of response or occurrence of side effects.3 One of the important 
causes of loss of response is the development of anti-infliximab 
antibodies.4 Adalimumab has become a new treatment option 
for patients with CD who are either naive to, failed to respond 
to, or experienced loss of response to infliximab therapy.5-9 
Adalimumab, a recombinant, fully humanized immunoglobulin 
G1 monoclonal antibody, is theoretically less vulnerable to im-
munogenicity development. This drug has proved effective for 
remission induction and maintenance in Western CD patients. 
Despite the therapeutic efficacy of adalimumab, its efficacy in 
Korean patients is still unknown, and suitable patient character-
istics and the appropriate timing for administration with regard 
to phenotypic behavior, disease distribution, and disease activ-
ity have yet to be determined. Therefore, in the present study, 
we aimed to evaluate the efficacy of adalimumab in Korean 
patients with CD in a single tertiary academic center and deter-
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mine the predictors of a favorable response.
MATERIALS AND METHODS 
1. Patients 
A total of 62 patients with CD who were treated with adali-
mumab at a tertiary academic center in Korea between October 
2008 and December 2014 were included in this retrospective 
study. CD was diagnosed based on the assessment of location 
and extent of chronic intestinal mucosal inflammation through 
endoscopy with biopsies and radiological testing. The allow-
able indications for adalimumab therapy based on the National 
Health Insurance of Korea are as follows: (1) patients who be-
come nonresponsive to conventional therapy, including corti-
costeroids and immunomodulators; (2) patients with moderate 
to severe CD (Crohn’s disease activity index [CDAI] ≥220) who 
were contraindicated for conventional therapy; and (3) patients 
who have failed infliximab treatment.
Nonsmokers were defined as those who currently do not 
smoke cigarettes including both former smokers (ex-smokers) 
and never smokers. The Montreal classification was used for as-
sessing disease location and behavior.10 Patients with evidence 
of tuberculosis exposure via a protein-purified derivative skin 
test or interferon γ releasing assay for tuberculous antigen and 
a chest X-ray received antituberculosis prophylactic treatment 
before the initiation of adalimumab therapy. Adalimumab was 
contraindicated for patients with serious concurrent infection or 
malignancy, such as lymphoproliferative disorders.
Our study had ethical approval from the Severance Institu-
tional Review Board, but the requirement for informed consent 
was waived due to its retrospective design.
2. Assessment of disease activity
Most controlled clinical trials for CD define clinical remission 
as CDAI <150 points (CR-150) and clinical response as a reduc-
tion in CDAI of 70 points (CR-70) or a reduction in CDAI of 
100 points (CR-100) from baseline.11 CDAI score was assessed at 
weeks 4, 8, and 52. The proportion of patients achieving clini-
cal remission (CDAI<150) as well as the proportion of patients 
achieving CR-70 and CR-100 was assessed.
Data from all patients who achieved clinical remission 
(CDAI<150) at the end of the 8-week induction trial were ana-
lyzed with a univariate analysis. Patients who showed a clinical 
response, regardless of degree, at the end of the 8-week induc-
tion trial were enrolled in the analysis of the maintenance trial. 
Total follow-up time was determined from the start of therapy 
to the last date of adalimumab administration or adalimumab 
discontinuation.
3. Primary and secondary outcome analyses
The primary outcome analysis was to determine the propor-
tion of patients with an initial treatment response to and treat-
Table 1. Patient Demographic and Baseline Characteristics
Characteristic Value
Sex
    Male 36 (58.1)
    Female 26 (41.9)
Age at anti-TNF induction, yr 30.4±9.5 (15–52)
Duration of CD, yr
    ≤2 6 (9.7)
    2–5 12 (19.4)
    >5 44 (71.0)
Weight, kg 51.0±10.6 (34.0–87.0)
Tobacco usage, nonsmoker 58 (93.5)
Extraintestinal manifestation
    Arthritis 3 (4.8)
    Erythema nodosum 3 (4.8)
    Aphthous stomatitis 4 (6.5)
    Iritis/uveitis 4 (6.5)
Montreal classification, age at diagnosis 
    A1 12 (19.4)
    A2 49 (79.0)
    A3 1 (1.6)
Montreal classification, location 
    L1 14 (22.6)
    L2 4 (6.5)
    L3 44 (71.0)
    L4 5 (8.1)
Montreal classification, behavior 
    B1 39 (62.9)
    B2 10 (16.1)
    B3 13 (21.0)
Perianal disease 27 (43.5)
CDAI 301.0±79.3 (151.0–568.7)
BMI, kg/m2 18.4±3.3 (13.6–29.3)
CRP, mg/L 21.5±24.3 (0.2–115.8)
ESR, mm/hr 51.0±31.9 (2.0–120.0)
WBC, /mm3 6,687±2,483 (2,510–15,510)
Hematocrit, % 36.7±5.5 (21.8–47.5)
Albumin, g/dL  3.5±0.6 (2.0–4.6)
Indication of adalimumab use
    Both anti-TNF agent and 
      azathioprine-naive 
0
    Anti-TNF agent-naive+azathioprine 21 (33.9)
    Inflixmab failure 41 (66.1)
Data are presented as mean±SD (range) or number (%).
TNF, tumor necrosis factor; CD, Crohn’s disease; CDAI, Crohn’s dis-
ease activity index; BMI, body mass index; CRP, C-reactive protein; 
ESR, erythrocyte sedimentation rate; WBC, white blood cell.
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ment maintenance with adalimumab. The secondary outcome 
analysis was to assess the predictors associated with inducing 
and maintaining clinical remission.
4. Statistical analysis
All statistical analyses were performed using SPSS version 
18.0 (SPSS Inc., Chicago, IL, USA), and a two-sided p-value 
<0.05 was considered to be statistically significant. The chi-
square test or Fisher exact test was used for the comparison 
of categorical data to determine clinical factors predictive of 
clinical response at week 8, and odds ratios (ORs) were provided 
where necessary.
The sustained clinical benefit of adalimumab was estimated 
with Kaplan-Meier analyses. To compare hazard ratios defined 
by one variable at the time, the log-rank test was used. Logistic 
and Cox proportional hazard models were conducted to detect 
predictors of clinical response to adalimumab treatment. 
Table 2. Univariate Analysis of Variables for Clinical Remission at Week 8
Variable Remission (n=28) Nonremission (n=34) OR 95% CI p-value
Male sex 21 (75.0) 15 (44.1) 3.800  1.277–11.312 0.014
Nonsmoker 24 (85.7) 34 (100.0) 2.471 1.779–3.283 0.023
Disease duration, yr
    ≤2 4 (14.3)  5 (14.7) 2.667  0.451–15.781 0.265
    2–5 7 (25.0) 27 (79.4) 1.933 0.539–6.937 0.307
    >5 17 (60.7) 12 (35.3) 0.401 0.130–1.235 0.107
Induction regimen, mg
    160/80 15 (53.6) 12 (35.3) 2.115 0.761–5.883 0.149
    80/40 13 (46.4) 22 (64.7) 0.453 0.163–1.257 0.126
History of bowel resection 11 (39.3) 20 (58.8) 0.453 0.163–1.257 0.126
    Naive to anti-TNF agents 15 (53.6)  6 (17.6) 5.385  1.700–17.054 0.003
Montreal classification
    Age a diagnosis
        A1 8 (28.6)  4 (11.8) 3.000  0.796–11.308 0.096
        A2 20 (71.4) 29 (85.3) 0.431 0.123–1.511 0.182
        A3 0 1 (2.9) 0.541 0.429–0.682 0.360
    Disease location
        L1 10 (35.7)  4 (11.8) 4.167  1.137–15.265 0.025
        L2 2 (7.1) 2 (5.9) 1.231 0.162–9.344 0.841
        L3 16 (57.1) 28 (82.4) 0.286 0.090–0.908 0.030
        L4 3 (10.7) 2 (5.9) 1.920  0.298–12.384 0.487
    Disease behavior
        B1 17 (60.7) 22 (64.7) 0.843 0.300–2.372 0.746
        B2 7 (25.0) 3 (8.8) 3.444  0.799–14.855 0.085
        B3 4 (14.3)  9 (26.5) 0.463 0.126–1.706 0.241
Perianal disease 10 (35.7) 17 (50.0) 0.556 0.199–1.548 0.259
Medication 
    Azathioprine 16 (57.1) 12 (35.3) 2.333 0.832–6.543 0.105
    Prednisolone 5 (17.9) 3 (8.8) 2.303 0.802–6.610 0.312
    5-ASA 23 (82.1) 30 (88.2) 0.460 0.100–2.126 0.312
Disease activity
    Mild 4 (14.3) 2 (5.9) 2.667 0.451–15.781 0.265
    Moderate 24 (85.7) 30 (88.2) 0.800 0.181–3.536 0.768
    Severe 0 2 (5.9) 0.533 0.421–0.676 0.192
Data are presented as number (%).
OR, odds ratio; CI, confidence interval; TNF, tumor necrosis factor; 5-ASA, 5-aminosalicylate.
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RESULTS 
1. Patient baseline characteristics
Baseline clinical characteristics of 62 patients with CD (36 
male; mean age, 30.4 years; range, 15 to 52 years) are shown 
in Table 1. Their mean baseline CDAI score was 301; 9.7% of 
patients had mild disease activity (150≤CDAI<220), 87.1% had 
moderate disease activity (220≤CDAI<450), and 3.2% had severe 
disease activity (CDAI≥450) at enrollment. The six patients who 
were administered adalimumab despite low disease activity had 
undergone multiple bowel resections. They were at high risk for 
developing short bowel syndrome and other intestinal compli-
cations. Eight patients received antituberculosis prophylactic 
treatment before the initiation of adalimumab therapy. Forty-
one of 62 patients (66.1%) had previously failed to respond to 
or had experienced loss of response to infliximab. 
Six patients (9.7%) presented with at least one extra-intestinal 
manifestation at baseline. Three patients (4.8%) had peripheral 
arthralgia, four (6.5%) had ocular manifestations, four (6.5%) 
had aphthous stomatitis, and the remaining three (4.8%) had 
erythema nodosum.
2. Outcomes at week 8
Of the 62 patients included in this analysis, three (4.8%) 
discontinued adalimumab therapy by week 8 due to primary 
nonresponse. Twenty-eight patients (45.2%) showed complete 
remission, 35 (56.5%) showed CR-100, and 41 (66.1%) showed 
CR-70 by week 8. The remaining 18 patients (29.0%) continued 
receiving adalimumab therapy in an effort to achieve a delayed 
response, although their initial responses were considered un-
satisfactory.
To determine factors predictive of clinical remission at week 8, 
univariate unadjusted ORs were calculated (Table 2). Male sex, 
nonsmoker, naive status to an anti-TNF agent, and ileal disease 
were associated with clinical remission at week 8. Twenty-eight 
patients (45.2%) received combination therapy with adalim-
umab and azathioprine, which did not increase the complete 
remission rate at week 8 on univariate analysis (p=0.105). 
A multivariate analysis revealed that naive status to an anti-
TNF agent (OR, 5.120; 95 confidence interval [CI], 1.416 to 
18.509) and ileal disease (OR, 4.708; 95% CI, 1.087 to 20.391) 
were independent predictors of clinical remission at week 8 (Table 3).
3. Outcomes at week 52
In total, 38 patients (61.3%) were still being treated with 
adalimumab by the end of follow-up. Twenty patients (32.3%) 
showed complete remission, 28 (45.2%) showed CR-100, and 32 
(51.6%) showed CR-70 by 52 weeks (Fig. 1).
On univariate analysis, Montreal classification A3 and mild 
disease severity were associated with loss of response at week 
52 (p=0.019 and p=0.013, respectively) (Table 4). On multivari-
ate analysis, Montreal classification A3 and mild disease activity 
were independently associated with clinical relapse at week 52 
(Table 5).
Thirty-six patients (58%) received concurrent azathioprine 
therapy, which did not affect treatment outcome (log-rank test, 
p=0.484). Two patients developed herpes zoster during adali-
mumab therapy, but life-threatening side effects did not occur 
during the adalimumab treatment.
DISCUSSION 
The purpose of this study was to evaluate the efficacy of 
adalimumab as induction and maintenance therapy for CD in 
Korea. Therapeutic strategies in CD patients treated with adali-
mumab have not been well evaluated compared to those with 
infliximab. Under the step-up approach, patients who are un-
responsive and intolerant to 5-aminosalicylate, corticosteroids, 
azathioprine, and/or infliximab are switched to adalimumab 
therapy. Adalimumab became an additional treatment option in 
patients who had lost response to or were intolerant to conven-
tional treatments. In addition, adalimumab can be used before 
infliximab therapy in patients with failure to respond to con-
ventional therapy.

























Fig. 1. Clinical response to and remission rates after adalimumab 
therapy. 
CR-70, clinical response based on a reduction of 70 points in the 
Crohn’s disease activity index (CDAI); CR-100, clinical response based 
on a reduction of 100 points in the CDAI from baseline; Remission, 
CDAI <150 points.
Table 3. Multivariate Logistic Regression Analysis of Predictors As-
sociated with Clinical Remission at Week 8
Predictor OR 95% CI p-value
Naive to biological agent 5.120 1.416–18.509 0.013
Montreal classification, L1 4.708 1.087–20.391 0.038
Montreal classification, A1 4.202 0.914–19.321 0.065
Induction regimen, 160/80 mg 1.834 0.529–6.366 0.339
OR, odds ratio; CI, confidence interval.
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In our study, 35 of 62 patients (56.5%) achieved clinical re-
sponse (change in the CDAI≥100), including 28 (45.2%) who 
achieved complete remission at week 8 of the induction therapy. 
More than half of patients with CD showed an initial clinical 
benefit from adalimumab therapy as an induction therapy.
The induction benefits of adalimumab for patients with active 
CD were first demonstrated in the CLASSIC (Clinical Assessment 
of Adalimumab Safety and Efficacy Studied as an Induction 
Therapy in Crohn’s) I trial. The remission rate at week 4 for pa-
tients administered the higher 160/80 mg adalimumab dosing 
was significantly different from that for patients receiving pla-
cebo (36% vs 12%, respectively, p=0.001). Clinical response rate 
(change in the CDAI≥100) for the higher adalimumab dosing 
schedule was also significantly different from that of placebo at 
week 4 (50% for the 160/80 mg adalimumab group vs 25% for 
placebo, p=0.002).5 In this study, the predictors of response to 
anti-TNF-α therapy in CD included a short duration of disease 
and inflammatory disease, colonic disease, less severe disease, 
and nonsmoking.12
In our study, nonsmoker, naive status to an anti-TNF agent, 
and a Montreal classification of L1 for disease location were as-
sociated with an increased complete remission rate on univari-
ate analysis. A multivariate analysis revealed that naive status 
to an anti-TNF agent (OR, 5.120; 95 CI, 1.416 to 18.509) and 
a Montreal classification of L1 for disease location (OR, 4.708; 
95% CI, 1.087 to 20.391) were independent predictors for clini-
cal remission at week 8. Our results are consistent with those of 
previous studies in that nonsmokers and patients naive to an 
anti-TNF agent showed better response during induction ther-
apy. It is well known that patients with a primary nonresponse 
or loss of response to one anti-TNF agent have a suboptimal 
response to a second agent.13 Patients naive to anti-TNF therapy 
showed a better response to adalimumab. Clinical remission 
rates were approximately 53.6% (p=0.003) in patients naive to 
anti-TNF therapy compared with 17.6% in patients who had 
been treated with infliximab. These results could be due to a 
very similar mode of action for both drugs. However, immuno-
genicity is completely different between the two drugs. Approx-
imately 10% to 30% of patients per year discontinue infliximab 
therapy because of loss of response or side effects.3 Introduction 
of adalimumab after failure of infliximab therapy resulted in 
sustained clinical benefits in 50% to 60% of patients.14
It is well known that determining disease behavior and the 
location of the lesions is of paramount importance at the timing 
of drug administration. Small bowel and anoperineal involve-
ment at diagnosis were predictors of early structuring or pen-
etrating complications. However, L1 disease was associated with 
a higher clinical remission rate in our study, which was different 
from data from other trials.13,15,16 The reasons for this discrep-
Table 4. Univariate Analysis of Variables for Clinical Relapse during 
Adalimumab Therapy (Log-Rank Test)
Predictor p-value
Male sex 0.074
Duration of Crohn’s disease, yr
    ≤2 0.185
    2–5 0.288
    >5 0.701
Tobacco use, nonsmoker 0.645
Montreal classification, age at diagnosis 
    A1 0.508
    A2 0.970
    A3 0.019
Montreal classification, location 
    L1 0.422
    L2 0.886
    L3 0.568
    L4 0.698
Montreal classification, behavior 
    B1 0.856
    B2 0.281
    B3 0.550
Perianal disease 0.096
History of bowel resection 0.893
Medication at administration of ADA
    Azathioprine 0.105
    Prednisolone 0.547
    5-ASA 1.000
CDAI severity
    Mild 0.013
    Moderate 0.064
    Severe 0.726
Prior use of infliximab 0.955
Induction regimen, mg
    160/80 0.279
    80/40 0.279
Indications for therapy
    Drug resistant 0.226
    Penetrating disease 0.367
    Deep ulcer and extensive disease 0.353
ADA, adalimumab; 5-ASA, 5-aminosalicylate; CDAI, Crohn’s disease 
activity index. 
Table 5. Cox Predictive Factors for Clinical Relapse during Adalim-
umab Therapy
Predictor HR 95% CI p-value
Montreal A3 17.231 1.670–177.838 0.017
Mild CDAI severity  7.520 1.666–33.948 0.009
HR, hazard ratio; CI, confidence interval; CDAI, Crohn’s disease activ-
ity index.
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ancy are currently unknown and should be further investigated.
The mean duration of follow-up was 19.1 months (range, 1 to 
56 months), and the median was 14 months in our study. Main-
tenance therapy demonstrated continuous clinical remission 
over 52 weeks in 20 patients (32.3%). Clinical response (change 
in the CDAI≥100) was achieved in 28 patients (45.2%).
The long duration of the efficacy of adalimumab mainte-
nance therapy in CD was evaluated in a follow-up randomized 
controlled trial (CLASSIC II).7 Of 204 patients in the preceding 
CLASSIC I trial, 93 (46%) were in clinical remission at week 56. 
Recent post hoc subgroup analyses of the Crohn’s Trial of the 
Fully Human Antibody Adalimumab for Remission Mainte-
nance and Additional Long-term Dosing with Adalimumab to 
Evaluate Sustained Remission and Efficacy in Crohn’s Disease 
were performed.17 Predictors for loss of response or dose escala-
tion were male sex, current/former smoker status, family history 
of inflammatory bowel disease, isolated colonic disease, extrain-
testinal manifestations, 80/40 mg induction therapy, longer dis-
ease duration, greater baseline CDAI, concomitant corticosteroid 
use, no deep remission at week 12, low serum trough concen-
trations of adalimumab, previous infliximab nonresponse, and 
being previously treated with an anti-TNF agent.18
Based on the Kaplan-Meier analysis and log-rank test results 
in our study, Montreal classification A3 and lower CDAI score 
were associated with poor long-term outcomes. In the Cox pro-
portional hazards model, the hazard ratio for maintenance of 
response was significantly higher for patients who showed mild 
CDAI severity and Montreal classification A3. Further studies 
are warranted to validate the current findings. One possible ex-
planation is that mild CDAI severity might be related to reasons 
other than bowel inflammation itself and Montreal classification 
A3 might reflect more extensive disease. Previous infliximab 
treatment did not alter clinical course on maintaining clinical 
remission contrary to inducing clinical remission.
The advantages of adalimumab and azathioprine combina-
tion therapy are still debating. Induction and maintenance 
therapy with azathioprine and adalimumab were shown to have 
no long-term advantages over adalimumab alone in a recent 
study.19 In our study, both baseline immunomodulator and 
concurrent immunomodulator combination with adalimumab 
did not increase the efficacy of anti-TNF therapy (log-rank test, 
p=0.484), which needs further validation.
No patient discontinued adalimumab due to adverse effects. 
The risk of opportunistic infections increases in patients receiv-
ing immunosuppressive medications, including corticosteroids, 
anti-TNF-α agents, and 6-mercaptopurine/azathioprine.20 Two 
patients contracted herpes zoster infection, and both of them 
were taking adalimumab with concurrent immunomodulators. 
There were no allergic reactions or serious infections. In a meta-
analysis of 21 studies including 5,356 individuals, anti-TNF 
therapy did not increase the risks of death, malignancy, or seri-
ous infection.21 There was no serious adverse effect in this study.
This is the first study from a Korean population, which is one 
of the strengths of our study. Moreover, it was investigated in 
real clinical practice setting. However, there are some limitations 
of our study, in that it was a retrospective study from a single 
center. The follow-up might not have been sufficiently long for 
evaluation. In addition, the assessment of mucosal healing plays 
a useful role in guiding therapeutic adjustment. Many studies 
showed a relatively poor correlation with CDAI in Crohn’s pa-
tients.22 The six patients with mild disease activity at induction 
did not reflect the real disease activity. Our study did not inves-
tigate the impact of endoscopy on clinical decision and disease 
monitoring, but regular endoscopic assessment is impractical in 
the clinical settings. Finally, only a small number of the overall 
studied patients were enrolled in our analysis. Multicenter stud-
ies with a larger number of patients would be warranted to draw 
a concrete conclusion to examine the efficacy of adalimumab in 
Korean patients with CD.
In conclusion, adalimumab is an effective treatment for the 
induction and maintenance of remission for CD. CD patient 
naive to anti-TNF therapy and Montreal classification L1 were 
associated with higher rates of clinical remission. Further studies 
are warranted to determine the prognostic factors for long-term 
response.
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